EGFR and lung cancer: In the US, around 10% to 15% of all lung cancer patients test positive for the EGFR mutation, and Asian patients have a higher EGFR mutation frequency (51.4% overall) in tumors.[36,37] Researchers discovered that drugs that inhibit the EGFR pathway may be helpful to prevent or restrain the growth of lung cancer cells with EGFR mutation.